Literature DB >> 13706053

Sulphinpyrazone in the treatment of arthritis associated with hyperuricaemia.

E N GLICK.   

Abstract

Entities:  

Keywords:  ARTHRITIS/therapy; PHENYLBUTAZONE/related compounds; URIC ACID/blood

Mesh：

Substances：

Year:  1961        PMID： 13706053      PMCID： PMC1869540     

Source DB:  PubMed          Journal:  Proc R Soc Med        ISSN： 0035-9157


× No keyword cloud information.
  6 in total

1.  Results of a clinical trial of G-28315, a sulfoxide analog of phenylbutazone, as a uricosuric agent in gouty subjects.

Authors:  T F YU; J J BURNS; A B GUTMAN
Journal:  Arthritis Rheum       Date:  1958-12

2.  Value of uricosuric agents and in particular of G. 28 315 in gout.

Authors:  G D KERSLEY; E R COOK; D C TOVEY
Journal:  Ann Rheum Dis       Date:  1958-09       Impact factor: 19.103

3.  Use of the newer uricosuric agents in the management of gout.

Authors:  J E SEEGMILLER; A I GRAYZEL
Journal:  JAMA       Date:  1960-07-09       Impact factor: 56.272

4.  A potent new uricosuric agent, the sulfoxide metabolite of the phenylbutazone analogue, G-25671.

Authors:  J J BURNS; T F YU; A RITTERBAND; J M PEREL; A B GUTMAN; B B BRODIE
Journal:  J Pharmacol Exp Ther       Date:  1957-03       Impact factor: 4.030

5.  Evaluation of uricosuric agents in chronic gout.

Authors:  M A OGRYZLO; J HARRISON
Journal:  Ann Rheum Dis       Date:  1957-12       Impact factor: 19.103

6.  Quantitation of the manifestations of rheumatoid arthritis. 4. Area of joint surfaces as an index to total joint inflammation and deformity.

Authors:  J LANSBURY; D D HAUT
Journal:  Am J Med Sci       Date:  1956-08       Impact factor: 2.378
  6 in total
  1 in total

Review 1.  Antirheumatic drugs: clinical pharmacology and therapeutic use.

Authors:  G L Craig; W W Buchanan
Journal:  Drugs       Date:  1980-12       Impact factor: 9.546
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.